Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
14.26
+0.35 (2.52%)
Aug 13, 2025, 4:00 PM - Market closed
Dr. Reddy's Laboratories Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Dr. Reddy's Laboratories stock ranges from a low of $16.9 to a high of $17. The average analyst price target of $16.95 forecasts a 18.86% increase in the stock price over the next year.
Price Target: $16.95 (+18.86%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 5, 2025.
Analyst Ratings
The average analyst rating for Dr. Reddy's Laboratories stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HSBC | HSBC | Hold → Strong Buy Upgrades $14 → $17 | Hold → Strong Buy | Upgrades | $14 → $17 | +18.51% | Jun 5, 2025 |
| Barclays | Barclays | Buy Maintains $17 → $17 | Buy | Maintains | $17 → $17 | +19.21% | Nov 6, 2024 |
| Barclays | Barclays | Buy Maintains $16 → $17 | Buy | Maintains | $16 → $17 | +22.02% | Jul 30, 2024 |
| Barclays | Barclays | Buy Maintains $16 → $16 | Buy | Maintains | $16 → $16 | +13.60% | May 8, 2024 |
| Barclays | Barclays | Buy Maintains $15 → $16 | Buy | Maintains | $15 → $16 | +12.20% | Jan 29, 2024 |
Financial Forecast
Revenue This Year
350.31B
from 325.54B
Increased by 7.61%
Revenue Next Year
356.95B
from 350.31B
Increased by 1.89%
EPS This Year
72.80
from 67.78
Increased by 7.41%
EPS Next Year
58.36
from 72.80
Decreased by -19.83%
Financial currency is INR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 382.9B | 404.3B | 449.1B | |
| Avg | 350.3B | 356.9B | 387.8B | |
| Low | 296.7B | 318.9B | 345.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 17.6% | 15.4% | 25.8% | |
| Avg | 7.6% | 1.9% | 8.6% | |
| Low | -8.8% | -9.0% | -3.2% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | 93.45 | 86.28 |
| Avg | 72.80 | 58.36 |
| Low | 58.02 | 34.59 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | 37.9% | 18.5% |
| Avg | 7.4% | -19.8% |
| Low | -14.4% | -52.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.